Thermo Fisher Scientific Inc. $TMO Position Reduced by Security National Bank of Sioux City Iowa IA

Security National Bank of Sioux City Iowa IA trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,527 shares of the medical research company’s stock after selling 121 shares during the quarter. Thermo Fisher Scientific makes up 2.4% of Security National Bank of Sioux City Iowa IA’s portfolio, making the stock its 7th biggest holding. Security National Bank of Sioux City Iowa IA’s holdings in Thermo Fisher Scientific were worth $3,248,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $25,000. Ameriflex Group Inc. acquired a new position in Thermo Fisher Scientific in the fourth quarter valued at $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at $31,000. IMA Advisory Services Inc. acquired a new position in Thermo Fisher Scientific in the first quarter valued at $35,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in Thermo Fisher Scientific in the first quarter valued at $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock valued at $14,182,963 over the last quarter. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.8%

Shares of NYSE TMO opened at $483.80 on Wednesday. The company has a market cap of $182.69 billion, a price-to-earnings ratio of 27.98, a price-to-earnings-growth ratio of 2.60 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock’s 50 day simple moving average is $463.59 and its 200 day simple moving average is $452.20.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same period last year, the firm earned $5.37 EPS. The firm’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

Analyst Upgrades and Downgrades

TMO has been the subject of several research analyst reports. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Evercore ISI decreased their target price on Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating for the company in a research report on Tuesday, July 8th. Barclays upped their target price on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 24th. UBS Group increased their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a report on Thursday, July 24th. Finally, HSBC reissued a “hold” rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $589.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.